Our IP Portfolio

Pro-Cure has a pipeline agreement with the University of York and Yorkshire Cancer Research which assigns all IP generated by the YCR Cancer Research Unit to the Company.

The Company already has a strong international patent portfolio relating to prostate drug targets, second medical use, prostate cancer stem cell models, the isolation of cancer stem cells and also baculovirus gene therapy vector technology.Pro-Cure is likely to generate significantly more intellectual property in the future.
Join the Pro-Cure Team - Vacancies for Research Technicians: Validation of oncology targets in vitro (Job advertisement 24 February 2010)
The Company: Pro-Cure Therapeutics Limited is a young, innovative Bio...
Pro-Cure Therapeutics appoints Alastair Riddell as Chairman (Press Release 1 October 2009)
York, United Kingdom, 1 October 2009. Pro-Cure Therapeutics Ltd (P...
Pro-Cure Founder and CSO receives prestigious award for work in cancer research (Press Release 23 June 2009)
Professor Norman Maitland, founder and CSO of Pro-Cure Therapeutics Li...
UK Biotech companies join forces to develop novel prostate cancer vaccine (Press Release 14 May 2009)
York and Sheffield, United Kingdom. 14 May 2009. Pro-Cure Therapeut...
Cancer Research Company's £2 Million Boost (Press Release 27 January 2009)
A biotech company working on human cancer stem cells has secured a £2 ...